Close Menu

antibodies

Merck, Medarex, and UMass' MBL Ink mAb deal; Vandy licenses cancer Rx assay to DiaTech; MolecularMD sub-licenses OHSU CML mutation test to Mayo Clinic, and more …

The CB1000 is the company's maiden commercial launch and comes amid a tumultuous year in which changes took place in top management.

The companies will combine marketing efforts for their antibodies and proteomics assays.

The company aims to tackle the two major issues in the antibody field — poor quality and too few antibodies — by defining a so-called "affome," an antibody set against all proteins in the human proteome.

Citing the FDA's handling of KRAS testing for anti-EGFR monoclonal antibodies, the report asserts that in the near term complex genetic tests such as Oncotype DX should be "performed through CLIA labs, and not held up by slow regulatory processes."

Several of the company's microarray-based tests have been certified in China and Europe.

Regeneron Inks mAb Pact with UT-Southwestern; Mount Sinai taps DiscoveryBioMed for bioassay services; Repligen licenses bipolar disorder Rx from Harvard's McLean, and more …

As part of the deal, Merck will pay Xencor a $3 million upfront license fee, make an additional payment if it selects an Xtend variant, and pay clinical development milestones and royalties on product sales.

Genomics vs. Cancer

Premium

Recent advances in the battle against cancer have come from sequencing, microRNAs, barcode arrays, disease stratification, pathway analysis, and more.

NKT licensed the IP from Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Massachusetts General Hospital. As a result, each of the Harvard Med-affiliated institutes has been awarded an undisclosed equity stake in the company.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.